Compare SMX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMX | AMPH |
|---|---|---|
| Founded | N/A | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2014 |
| Metric | SMX | AMPH |
|---|---|---|
| Price | $50.60 | $27.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.00 |
| AVG Volume (30 Days) | ★ 1.4M | 375.1K |
| Earning Date | 04-23-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.27 |
| Revenue | N/A | ★ $723,305,000.00 |
| Revenue This Year | N/A | $1.35 |
| Revenue Next Year | N/A | $5.10 |
| P/E Ratio | ★ N/A | $11.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.12 | $20.39 |
| 52 Week High | $66,187.38 | $39.01 |
| Indicator | SMX | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 55.28 |
| Support Level | $110.11 | $26.26 |
| Resistance Level | $198.00 | $27.23 |
| Average True Range (ATR) | 40.39 | 0.76 |
| MACD | -15.11 | 0.06 |
| Stochastic Oscillator | 2.05 | 85.96 |
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.